AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00645593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab will be administered intravenously at a dose of 500 mg/m2 on Days 1 and 15 of each cycle. One treatment cycle is 28 days.
Study NCT00404690 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bedside Silo
Description: silo placed at bedside on admission
Study NCT00404690 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Operative attempt at closure
Description: go the operating room to attempt closure
Study NCT04169880 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HILT
Description: HILT will be performed with BTL 6000 High Intensity Laser (London, UK) which is a therapeutic non-invasive neodymium: yttrium aluminum garnet laser that has a pulsating waveform and 1064 nm wavelength, 12 Watt maximum power and has the ability to penetrate 12 cm.
Study NCT04169880 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: HILT & EXERCISE
Description: HILT\&Exercise group will receive exercise therapy right after they receive HILT. Both groups will receive treatment for 3 days a week, on alternate days and totally 10 sessions. Patients will be asked not to use analgesic medication throughout the treatment period.
Study NCT04376320 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: customised ceramic sheets (Group 1)
Description: guided bone regeneration
Study NCT04376320 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: modified sausage technique (Group 2)
Description: guided bone regeneration
Study NCT00821080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Taken orally at different dose levels depending upon enrollment time period
Study NCT00821080 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: Taken orally at different dose levels depending upon enrollment time period
Study NCT00427076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cotrimoxazole
Description: Cotrimoxazole arm: intravenous cotrimoxazole 4 amp (320 mg trimethoprim/ 1600 mg sulfamethoxazole) diluted in 500 ml D5W or N.S. Q 12 hours. Patients intolerant of volume overload will be given the same dose in 250ml D5W (as in the current recommendations used in the hospital). The dose was selected basing on the existing randomized controlled trial and a pharmacokinetic study . 21 For patients with GFR\< 30 the dosage interval will be increased to 4 amp (320 mg trimethoprim/ 1600 mg sulfamethoxazole) diluted in 500 ml D5W or N.S. Q 24 hours. 22 Patients on peritoneal dialysis will be given 2 amp (160 mg trimethoprim/ 800 mg sulfamethoxazole) Q 48 hours. Patients with acute renal failure treated with hemodialysis will be given the 2 amp (160 mg trimethoprim/ 800 mg sulfamethoxazole) after dialysis. Patients on continuous hemofiltration for acute renal failure will be administered the dose for GFR\<30.
Study NCT00427076 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vancomycin
Description: intravenous vancomycin 1gr Q 12 hours. Adjustment to creatinine clearance: GFR 10-50 1 gr Q 24-96 hours, GFR \<10 1gr Q 4-7 days.
Study NCT00363948 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Double-blind period (12 wk); Placebo QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
Study NCT00363948 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin phosphate
Description: Double-blind period (12 wk); 50 mg QD The double-blind period will be followed by a 40 wk open-label extension period where MK-0431/ONO-5435 could be titrated from 50 mg QD to 100 mg QD
Study NCT04261075 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPH5201
Description: Ascending dose levels of IPH5201 every 3 weeks (Q3W) for a maximum of 2 years
Study NCT04261075 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: durvalumab
Description: Durvalumab Q3W for a maximum of 2 years
Study NCT04261075 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: oleclumab
Description: Oleclumab Q3W for a maximum of 2 years
Study NCT01890642 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: J tip
Description: This is a Jet Injection system which for our study will be loaded with 1% buffered lidocaine
Study NCT01890642 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: J tip
Description: This is a Jet Injection system which for our study will be loaded with 1% buffered lidocaine
Study NCT01890642 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Pain Ease Spray
Description: Cold Spray used to anesthetize the skin
Study NCT01890642 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Pain Ease Spray
Description: Cold Spray used to anesthetize the skin
Study NCT01890642 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1% buffered lidocaine
Description: Lidocaine placed using Jet Injection
Study NCT01890642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo cooling spray (normal saline spray)
Description: Normal Saline Sprayed as placebo for Pain Ease spray
Study NCT01890642 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sucrose
Description: Oral Sucrose used for children \< 1 year
Study NCT01890642 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sucrose
Description: Oral Sucrose used for children \< 1 year
Study NCT01890642 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Sucrose
Description: Oral Sucrose used for children \< 1 year
Study NCT03765138 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PE/Pramipexole
Description: Experimental: PE/Pramipexole Prolonged Exposure (PE) Therapy consists of 10 sessions of 90-minute duration, normally conducted once a week. Elements of PE include imaginal and in vivo exposure to trauma reminders; breathing retraining; cognitive restructuring; and PTSD psychoeducation.~Pramipexole: In addition to receiving PE as described above, patients will have Pramipexole treatment. Daily dose will be started at 0.25 mg/day and increased by 0.25 mg/day every 3-4 days to a target of 2.5mg day by week 5. Beginning week 6 daily dose will be increased weekly by 0.5 mg/day to a maximum dose of 4mg. Dose will be increased as tolerated unless the patient has achieved remission and will be decreased in the event of intolerable adverse events.
Study NCT01970501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bucindolol hydrochloride
Study NCT01970501 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metoprolol succinate
Study NCT00801177 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-11F8
Description: Cohort 2~200 mg I.V.
Study NCT00801177 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-11F8
Description: Cohort 3~400 mg I.V.
Study NCT01970501 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo oral capsule
Study NCT00801177 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-11F8 I.V.
Description: Cohort 4~600 mg I.V.
Study NCT00801177 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-11F8
Description: Cohort 5~800 mg I.V.
Study NCT00801177 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-11F8
Description: Cohort 6~1000 mg I.V.
Study NCT00794157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 150 μg capsules
Description: Indacaterol was supplied in powder filled capsules with a single dose dry powder inhaler (SDDPI).
Study NCT00794157 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indacaterol 300 μg capsules
Description: Indacaterol was supplied in powder filled capsules with a single dose dry powder inhaler (SDDPI).
Study NCT00794157 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo capsules
Description: Placebo was supplied in powder filled capsules with a single dose dry powder inhaler (SDDPI).
Study NCT03632733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline
Description: Tetracycline cream
Study NCT03632733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clotrimazole
Description: Clotrimazole cream
Study NCT03632733 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tetracycline and Clotrimazole
Description: Combination cream
Study NCT03632733 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo cream without active drug ingredients
Study NCT02854644 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: additional blood sample
Study NCT00912002 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-0941
Description: A single dose of 40 mg of \[14C\]MK-0941 (160 µCi), taken orally as eight 5-mg capsules
Study NCT02745587 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiotherapy
Description: high dose external beam radiotherapy limited to the prostate(bed)
Study NCT02745587 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiotherapy
Description: high dose external beam radiotherapy limited to the prostate(bed)
Study NCT03817775 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Music therapy
Description: The intervention group will administer U sequence between 10 minutes prior to the beginning of the procedure until its end.
Study NCT00814892 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: allogeneic tumor cell vaccine
Description: Given intradermally
Study NCT00814892 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous dendritic cells
Description: Given intradermally
Study NCT01632995 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC 200 mg/TDF 300 mg fixed-dose combination tablet
Description: Each participant will be directed to take one FTC/TDF tablet orally once a day, with or without food.
Study NCT04100889 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention for this study.
Study NCT01325922 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: DFT Testing with a 50/50% tilt
Study NCT00710476 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Insemination
Description: Insemination with a lower concentration of spermatozoa: 150 000 spermatozoa/ml
Study NCT00890032 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BTSC mRNA-loaded DCs
Description: An escalating total dose of BTSC mRNA-loaded DCs (2x10\^6, 5x10\^6, and 2x10\^7 per vaccination) will be evaluated for purpose of establishing a maximum tolerated dose (MTD) and a dose-limiting toxicity (DLT).
Study NCT01361776 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: FSME-immune
Description: 0.5 ml im as scheduled in the 4 arms
Study NCT00677014 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AV Delay programming through cardiac resynchronization therapy
Description: All subjects in this trial receive the same device. For the purpose of this trial. intervention is programming of the atrio-ventricular (AV) delay in the two treatment arms, while the control arm will receive AV delay programming from a Fixed nominal setting. Echo optimized and Algorithm optimized are the treatment arms programmed to receive optimized AV delay settings and will be compared to the Fixed nominal arm.
Study NCT00950768 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Autologous transplantation
Description: Tandem autologous transplantation Melphalan 100 mg/m2 versus Melphalan 200 mg/m2
Study NCT00950768 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous transplantation
Description: Tandem autologous transplantation Melphalan 100 mg/m2 versus Melphalan 200 mg/m2
Study NCT04338035 — intervention group
Intervention type: BEHAVIORAL
Intervention: Expectant management
Description: Patients did not undergo surgical treatment for endometriosis and medical consultations were done every 6 months from the beginning of the attempts to conceive
Study NCT03115567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Description: 6 weeks of twice daily application of 0.1% triamcinolone cream to the face, chest, and back.
Study NCT03898375 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Walking with different optic flow speeds
Description: Patients will perform 4 sessions of 20 minutes treadmill walking: one control session without VR and 3 walking sessions with the VR. In each VR session, patients will walk with a different optic flow speed: the same as, faster than or slower than their walking speed.
Study NCT03065907 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vision rehabilitation
Description: A service menu containing the minimum vision rehabilitation visits will be provided and assessed according to the participant's vision needs. Minimum vision rehabilitation visits include refraction, best-corrected visual acuity assessment, near vision, contrast sensitivity, central visual field test, education and consultation; rehabilitation visit will then be individualized.
Study NCT01513421 — intervention group
Intervention type: PROCEDURE
Intervention: Percutaneous drainage of intra-abdominal collection
Description: Percutaneous drainage of infected intra-abdominal collection Under computed tomography or ultrasound guidance.~Procedures perform by a board certified interventional radiologist
Study NCT04398875 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupuncture and standard care (ASC)
Description: A semi-standardized treatment protocol and standard care will be employed.
Study NCT04398875 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham acupuncture and standard care (SSC)
Description: Validated non-insertion sham acupuncture (Streitberger sham acupuncture) and standard care will be applied.
Study NCT04398875 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard care (SC)
Description: Standard care will be employed.
Study NCT02237521 — intervention group
Intervention type: OTHER
Intervention: Eu- and hyperglycemic clamp
Description: Eu- and hyperglycemic clamp with concomitant infusion of the natural occurring hormones glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic peptide (GIP) or placebo along with stable glucose isotope infusion to measure the effects of the incretins.
Study NCT02237521 — intervention group
Intervention type: OTHER
Intervention: Arginine test
Description: Bolus infusion of the natural occurring amino acid arginine to measure the ability to increase the secretion of insulin and glucagon
Study NCT00801177 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMC-11F8
Description: Cohort 4~600 mg I.V.
Study NCT02142777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S -Equol
Description: We will determine if the intervention (S-equol) alters platelet mitochondria COX activity.
Study NCT02142777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo has no active ingredients but is made to look like the study drug.
Study NCT04253795 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laryngeal mask
Description: After the laryngeal mask will be inserted lung isolation will be achieved with an artificial pneumothorax induced during opening the pleura, which resulted to the collapse of the nondependent lung with the patient's spontaneous breathing.
Study NCT04253795 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: double lumen tube
Description: After the one lung ventilation will be started, lung isolation will be achieved by deflation of the nondependent lung.
Study NCT00761514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Humira (adalimumab)
Description: 40 mg eow
Study NCT01040455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: lansoprazole 15mg (Takepron®, Takeda Pharmaceutical Company, Osaka, Japan) once daily for eight weeks
Study NCT01040455 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo once daily for eight weeks
Study NCT03449095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alcohol
Description: Alcohol Target BAC .08%
Study NCT03527121 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ESP physiotherapy
Description: A single session with advice and instructions from an ESP physiotherapist in rest, ice, compression and elevation AND pain guided early weight bearing plus a written home-based exercise program.
Study NCT03527121 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: A single session with advice and instructions from a physician in rest, ice, compression and elevation (usual care group).
Study NCT06537713 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Testican-1
Description: Testican-1 and ubiquitin can serve as early indicators for diagnosing worsening clinical course and mortality in patients with moderate traumatic brain injury.
Study NCT01485939 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo patch applied
Description: Patients in this group would applied the placebo patch after laparoscopic cholecystectomy.
Study NCT01485939 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 5% lidocaine patch
Description: Patients in this group would applied the 5% lidocaine patch after laparoscopic cholecystectomy.
Study NCT02775396 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spectacle lens
Description: Wearing a spectacle lens design with corrective prescription power while playing computer game using an iPad tablet computer. Two lens designs were prescribed for each participant: the conventional single-vision lens and a new progressive addition lens designed for handheld digital device. Primary outcome measures were performed immediately after each lens delivery and one-month of lens wear.
Study NCT01685827 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fexinidazole
Study NCT01685827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nifurtimox
Study NCT01685827 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eflornithine
Study NCT03381716 — intervention group
Intervention type: DRUG
Intervention: drug
Description: Application bracket
Study NCT03381716 — intervention group
Intervention type: PROCEDURE
Intervention: Surgery
Description: Surgery
Study NCT01127568 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propranolol is available in generic form as the Wyeth product under the trade name Inderal.
Description: The study medication will consist of a dose of 2/3 mg/Kg of short-acting propranolol or placebo, followed 2 hours later by a dose of 1 mg/Kg of long-acting or placebo. The medication will be prescribed by the clinic's physician after medical check-up. A nurse will monitor blood pressure. According to, 40 mg of short-acting propranolol dose should produce a peak blood level of approximately 25 ng/ml at 2 hours, which the additional 60 mg long-acting propranolol should further increase by no more than 5ng. The decay of the blood level induced by the 40 mg short-acting dose after its 2-hour peak will outstrip the further rise induced by the 60 mg long-acting proposal dose, so that blood levels will not rise above this peak 30 ng/ml, which is within the therapeutic clinical range. If the participant tolerates the combination dose without any difficulty, during subsequent sessions, both the short- and long-acting doses will be given together immediately after memory reactivation.
Study NCT01127568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol is available in generic form as the Wyeth product under the trade name Inderal.
Description: The study medication will consist of a dose of 2/3 mg/Kg of short-acting propranolol or placebo, followed 2 hours later by a dose of 1 mg/Kg of long-acting or placebo. The medication will be prescribed by the clinic's physician after medical check-up. A nurse will monitor blood pressure. According to, 40 mg of short-acting propranolol dose should produce a peak blood level of approximately 25 ng/ml at 2 hours, which the additional 60 mg long-acting propranolol should further increase by no more than 5ng. The decay of the blood level induced by the 40 mg short-acting dose after its 2-hour peak will outstrip the further rise induced by the 60 mg long-acting proposal dose, so that blood levels will not rise above this peak 30 ng/ml, which is within the therapeutic clinical range. If the participant tolerates the combination dose without any difficulty, during subsequent sessions, both the short- and long-acting doses will be given together immediately after memory reactivation.
Study NCT04080193 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone-based interventional trial
Description: According to the SIRs the 12-week intervention will contain exercises from three out of six different key modules (e.g. self-efficacy, impulsivity). The remaining modules will be implemented as mini-modules during the end of the intervention phase. The study will be designed gender-sensitive instead of gender-dichotomous. This means that treatment contents will be individualized based on gender-related SIRs and not biological sex. Participants choose between two different styles of presentation for each module and the contents can be deepened within specific exercises.
Study NCT04116996 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEEP BRAIN STIMULATION
Description: NEUROMODULATION
Study NCT05617976 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: caudal block
Description: caudal block
Study NCT01439555 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin
Description: Simvastatin, 40 mg per day orally